EQT, Eurazeo Lead $700 Billion Wave of Firms Expanding in UAE
Sweden's EQT AB, France's Eurazeo and UK-based Pollen Street Capital are among those setting up in Abu Dhabi, according to people familiar with the matter. They'll join others including growth equity investor Baron Capital Management and credit-focused hedge fund Silver Point Capital Management, which have recently established a presence in Dubai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Stellus Capital Investment Corporation Announces $0.40 Third Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.1333 in August, September, and October 2025
HOUSTON, July 2, 2025 /PRNewswire/ -- Stellus Capital Investment Corporation (the "Company") (NYSE: SCM) announced that its Board of Directors has declared a monthly dividend of $0.1333 for each of July, August, and September, totaling $0.40 per share in the aggregate for the third quarter of 2025. The regular dividend of $0.40 per share will be paid to shareholders of record, as detailed in the table below. Summary of Third Quarter 2025 Regular Monthly Dividends Declared Ex-Dividend Date Record Date Payment Date Amount per Share 7/02/2025 7/31/2025 7/31/2025 8/15/2025 $0.1333 7/02/2025 8/29/2025 8/29/2025 9/15/2025 $0.1333 7/02/2025 9/30/2025 9/30/2025 10/15/2025 $0.1333 About Stellus Capital Investment Corporation The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company's investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien, second lien, unitranche and mezzanine debt financing, and corresponding equity investments. The Company's investment activities are managed by its investment adviser, Stellus Capital Management. To learn more about Stellus Capital Investment Corporation, visit under the "Public (SCIC)" link. FORWARD-LOOKING STATEMENTS Statements included herein may contain "forward-looking statements" which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. ContactsStellus Capital Investment CorporationW. Todd Huskinson, (713) 292-5414Chief Financial Officerthuskinson@ View original content to download multimedia: SOURCE Stellus Capital Investment Corporation
Yahoo
an hour ago
- Yahoo
Nvidia, TSMC, And AMD Surge As Trump's Mega Chip Push Leaves Intel Behind
July 2 - Chip makers rallied on Wednesday after the Senate approved boosting investment tax credits for U.S. semiconductor facilities to 35% from 25%. Intel (NASDAQ:INTC) shares slid about 3% following news its CEO may halt marketing of 18A technology to external clients, while Taiwan Semiconductor Manufacturing (NYSE:TSM) climbed about 3%. Micron Technology (NASDAQ:MU) added roughly 1%, and GlobalFoundries (NASDAQ:GFS) held steady. Warning! GuruFocus has detected 4 Warning Signs with NVDA. AI chip leaders also gained: Nvidia (NASDAQ:NVDA) surged about 3%, Advanced Micro Devices (AMD) rose around 2%, Broadcom (AVGO) edged up nearly 2%, and Qualcomm (QCOM) inched higher by about 1%. Smaller players saw similar moves. Lattice Semiconductor (LSCC) and Marvell Technology (MRVL) each jumped about 3%, Texas Instruments (TXN) rose 2%, and Analog Devices (ADI) added 1%. Equipment suppliers Applied Materials (NASDAQ:AMAT) and KLA (KLAC) climbed about 2% apiece, while ASML (ASML) and Lam Research (LRCX) were up about 1% each. The expanded credits build on the Biden administration's CHIPS and Science Act incentives. House lawmakers now aim to send the bill to President Trump by the July 4 deadline. Investors will watch whether the enhanced subsidies spur fresh U.S. chip plant announcements. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
This $125M Israeli Startup Is Building The World's First Cataract Robot To Solve A Global Crisis: 'There Is No Human Way To Close The Gap'
ForSight Robotics, an Israeli startup aiming to automate cataract and eye surgery, announced Tuesday that it raised $125 million to expand its precision robotics platform, Oryom. The round was led by Eclipse Ventures, with participation from surgical robotics legend Fred Moll, co-founder of Intuitive Surgical, and Moshe Shoham, a Technion professor and pioneer behind multiple robotics companies including Mazor, which was acquired by Medtronic for $1.6 billion, Forbes reports. Don't Miss: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Forbes says that more than 4 million cataract surgeries are performed each year in the U.S. alone. Yet, according to a World Health Organization report, over 1 billion people globally suffer from preventable vision loss. As the population ages and the number of ophthalmologists declines, a gap is forming that traditional medical systems can't fill. "There is no human way to close the gap as we see it," Dr. Joseph Nathan, ForSight co-founder and chief medical officer, told Forbes. "Robotics will have to take over." Cataract surgery is a highly precise procedure that involves operating within extremely small spaces, requiring steady hands and dexterous control, according to Forbes. ForSight says its Oryom platform is designed specifically to handle the complexity and consistency of ophthalmic procedures using AI-based algorithms, computer vision, and micromechanics to enhance surgical precision and reduce the physical strain on surgeons. Over the past year, more than two dozen ophthalmic surgeons have used the platform to successfully perform hundreds of procedures on animal eye models as part of the system's development and testing phase. Forbes reports that ForSight has specifically tested its robotic system on porcine eyes due to their close anatomical similarity to human eyes, a common method used in ophthalmic surgical training. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — The company says it has yet to perform surgery on a human patient, but expects to begin clinical trials by the end of the year. Early conversations with the Food and Drug Administration are already underway, and the new funding will carry the company through its regulatory process. ForSight was born out of Israel's Technion Institute, where Shoham, Nathan, and co-founder Daniel Glozman combined decades of expertise in medical engineering, research and development, and commercialization. Shoham's previous students have gone on to lead Medtronic's robotics division and build multi-billion-dollar exits. Moll and Shoham, often called "the godfathers of surgical robotics," now advise the company strategically, Forbes reports. "There is only one procedure that is done more than cataract surgery and that is blood drawing," Moll told Forbes. "As far as real surgical technique [that could be helped by robotics], cataract surgery is at the top of the list." With its third-generation prototype complete, ForSight is already preparing to expand its platform's capabilities beyond cataracts. Forbes says that future use cases include retinal procedures, glaucoma treatments, and complex eye surgeries that currently only a handful of surgeons in the world are qualified to Oryom system provides a potential answer to a looming global health crisis. According to the company, there are only 31.7 ophthalmologists and 14.1 cataract surgeons per million people globally, highlighting a significant gap between demand and surgical capacity. This surgeon shortage, combined with rising rates of preventable blindness, suggests that millions may not receive timely care. A 2020 study published in the British Journal of Ophthalmology, further confirms that lower-income countries average just 3.7 ophthalmologists per million people, compared to 76.2 in high-income nations, underscoring the disparity in access to eye care worldwide. By automating precision eye surgery, ForSight is betting on a future where access to vision care is no longer limited by geography or availability of human doctors. If successful, the company may become the Intuitive Surgical of ophthalmology. Read Next: Here's what Americans think you need to be considered wealthy. Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report This article This $125M Israeli Startup Is Building The World's First Cataract Robot To Solve A Global Crisis: 'There Is No Human Way To Close The Gap' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
